methylnaltrexone and Fecal-Impaction

methylnaltrexone has been researched along with Fecal-Impaction* in 1 studies

Other Studies

1 other study(ies) available for methylnaltrexone and Fecal-Impaction

Article	Year
[Successful treatment of treatment-resistant opioid-induced constipation in a patient with incomplete paraplegia with methylnaltrexone]. Schmerz (Berlin, Germany), 2009, Volume: 23, Issue:5 We observed a patient with incomplete, cervical paraplegia and opioid-induced constipation who developed a resistance to laxatives after 15 years of treatment. The constipation-induced reduction in the patient's quality of life was improved using 12 mg methylnaltrexone, a peripheral mu-opioid receptor antagonist, administered subcutaneously twice a week. Topics: Aged; Cervical Vertebrae; Constipation; Fecal Impaction; Humans; Injections, Subcutaneous; Male; Naltrexone; Narcotic Antagonists; Narcotics; Paraplegia; Postoperative Complications; Quaternary Ammonium Compounds; Spinal Cord Compression	2009

Article

Year

[Successful treatment of treatment-resistant opioid-induced constipation in a patient with incomplete paraplegia with methylnaltrexone].

Schmerz (Berlin, Germany), 2009, Volume: 23, Issue:5

We observed a patient with incomplete, cervical paraplegia and opioid-induced constipation who developed a resistance to laxatives after 15 years of treatment. The constipation-induced reduction in the patient's quality of life was improved using 12 mg methylnaltrexone, a peripheral mu-opioid receptor antagonist, administered subcutaneously twice a week.

Topics: Aged; Cervical Vertebrae; Constipation; Fecal Impaction; Humans; Injections, Subcutaneous; Male; Naltrexone; Narcotic Antagonists; Narcotics; Paraplegia; Postoperative Complications; Quaternary Ammonium Compounds; Spinal Cord Compression

2009